Biodesix (BDSX) CAO RSUs vest, tax-cover sale of 211 shares disclosed

Rhea-AI Filing Summary

Biodesix Inc Chief Accounting Officer Chris Vazquez reported equity transactions involving restricted stock units (RSUs) and common stock. On February 20, 2026, RSUs covering 563 shares were exercised for no cash cost, converting into the same number of common shares. Following this, on February 23, 2026, 211 common shares were sold in open-market transactions at a weighted average price of $12.7756 per share to cover taxes due upon RSU vesting, with individual sale prices ranging from $12.58 to $13.16. After these transactions, Vazquez directly held 1,586 common shares and 1,689 RSUs, with the RSUs scheduled to vest in four equal annual installments starting February 20, 2025.

Insider Trade Summary

Net Seller: 211 shares ($2,696)

Net Sell 3 txns

Insider Vazquez Chris

Role Chief Accounting Officer

Sold 211 shs ($3K)

Type	Security	Shares	Price	Value
Sale	Common Stock	211	$12.7756	$3K
Exercise	Restricted Stock Units	563	$0.00	--
Exercise	Common Stock	563	$0.00	--

Holdings After Transaction: Common Stock — 1,586 shares (Direct); Restricted Stock Units — 1,689 shares (Direct)

Footnotes (1)

1. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vazquez Chris

(Last) (First) (Middle)

919 WEST DILLON RD

(Street)

LOUISVILLE CO 80027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIODESIX INC [ BDSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/20/2026		M		563	A	(1)	1,797	D
Common Stock	02/23/2026		S(2)		211	D	$12.7756(3)	1,586	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/20/2026		M			563(4)	(5)	(5)	Common Stock	563(4)	$0	1,689(4)	D

Explanation of Responses:

1. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2. These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

3. The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

5. These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

	/s/ Robin H. Cowie as Attorney-in-Fact for Chris Vazquez	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Biodesix (BDSX) report for Chris Vazquez?

Biodesix reported that Chief Accounting Officer Chris Vazquez exercised restricted stock units for 563 common shares and sold 211 common shares in open-market transactions to cover tax obligations related to RSU vesting.

Was the Biodesix (BDSX) insider stock sale by Chris Vazquez discretionary?

The reported sale of 211 common shares by Chris Vazquez was automatically executed by the issuer’s broker solely to cover taxes due upon the vesting of RSUs, rather than being a discretionary open-market sale for personal liquidity.

At what price were Biodesix (BDSX) shares sold to cover Chris Vazquez’s RSU taxes?

The 211 Biodesix common shares sold for tax withholding were executed at a weighted average price of $12.7756 per share, with individual sale prices ranging from $12.58 to $13.16 in multiple transactions.

How many Biodesix (BDSX) shares does Chris Vazquez hold after these Form 4 transactions?

After the reported transactions, Chris Vazquez directly held 1,586 shares of Biodesix common stock and 1,689 restricted stock units, each RSU representing a contingent right to receive one share of common stock upon vesting.

How do Chris Vazquez’s Biodesix (BDSX) RSUs vest over time?

Chris Vazquez’s restricted stock units vest in four equal annual installments starting on February 20, 2025, generally conditioned on continued service with Biodesix, and each vested RSU delivers one share of the company’s common stock.

How were Biodesix (BDSX) Form 4 share numbers affected by the reverse stock split?

The share figures in the Form 4 reflect a one-for-twenty reverse stock split that became effective on September 15, 2025, meaning all reported share and RSU amounts have been adjusted to account for that reverse split.